Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP, PROOF OF CONCEPT STUDY OF THE ANALGESIC EFFECTS OF RN624 IN ADULT PATIENTS WITH POST-HERPETIC NEURALGIA

NCT00568321 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00568321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00568321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE II RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL GROUP, PROOF OF CONCEPT STUDY OF THE ANALGESIC EFFECTS OF RN624 IN ADULT PATIENTS WITH POST-HERPETIC NEURALGIA
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 19, 2007
Completion date
January 7, 2009
Enrollment
99 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

neuralgia, postherpetic